

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office :- Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

Date: 22nd October, 2019

To,
Bombay Stock Exchange Limited
Department of Corporate Services
25th Floor, P. J. Towers, Dalal Street,
Mumbai-400001

Script Id : 506365

Subject : **SUBMISSION OF COMPLIANCES UNDER SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015**

Dear Sirs,

We are enclosing herewith Quarterly Compliances pursuant to Securities And Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Quarter ended 30th September, 2019 as under -


1.	Regulation 33	Un-audited Quarterly and Half Yearly Financial Results along with Statement of Assets And Liabilities for the Quarter ended 30/09/2019 along with Limited Review Report issued by our Auditors, M/s. VMD & Co., Chartered Accountant, Mumbai
2.		Outcome of the Board Meeting Held on 22/10/2019

You are requested to take this on your records.

Thanking You.

Yours Faithfully,

FOR CHEMO PHARMA LABORATORIES LIMITED


ASHOK SOMANI
DIRECTOR
(DIN NO. - 03063364)





LIMITED REVIEW REPORT

We have reviewed the accompanying Statement of unaudited financial results of **M/S CHEMO PHARMA LABORATORIES LTD.**, Mumbai for the quarter ended **30th September, 2019**. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors / committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagement to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Dated: 07/10/2019
Place: Mumbai
UDIN: 19114222AAAAEL9592

For M/s VMD & CO.
Chartered Accountants.
FRN: 125002W


CA Amit Ganpule
Partner
MRN: 114222



CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301
 • Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001
 • Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K
 Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER 2019

		(Rupees in Thousand)					
Sr. No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30th Sept 2019	30th June 2019	30th Sept 2018	30th Sept 2019	30th Sept 2018	31st March 2019
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations						-
II	Other Income	2,779	2,831	1,299	5,610	2,539	8,225
III	Total Revenue (I + II)	2,779	2,831	1,299	5,610	2,539	8,225
IV	Expenses						
	(1) Cost Materials consumed	-	-	-	-	-	-
	(2) Purchase of Stock-in-Trade	-	-	-	-	-	-
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-	-
	(4) Employee Benefits Expenses	430	405	506	835	1,069	2,218
	(5) Depreciation and Amortisation Expenses	-	-	-	-	-	47
	(6) Administrative and Other Expenses	564	923	533	1,487	1,229	3,414
	i) Professional Charges	-	-	188	-	294	-
	ii) Annual Listing Fees	-	-	-	-	310	-
	iii) Travelling Expenses	-	-	-	-	268	-
	iv) Postal Charges	-	-	201	-	-	-
	(7) Finance Costs	-	-	-	-	-	-
	Total Expenses	994	1,328	1,428	2,322	3,170	5,679
V	Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)	1,785	1,503	(129)	3,288	(631)	2,546
VI	Exceptional Items	-	-	-	-	-	-
VII	Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)	1,785	1,503	(129)	3,288	(631)	2,546
VIII	Extra Ordinary Items	-	-	-	-	-	-
IX	Profit/(Loss) before Tax (VII-VIII)	1,785	1,503	(129)	3,288	(631)	2,546
X	Tax Expenses						
	(1) Current Tax	-	-	-	-	-	460
	(2) Tax Adjustment Previous Year	-	-	-	-	-	23
	(3) Deferred Tax	-	-	-	-	-	-
XI	Profit/(Loss) for the period from continuing operations (IX - X)	1,785	1,503	(129)	3,288	(631)	2,063
XII	Profit/(Loss) from discontinuing operations	-	-	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-	-	-	-	-
XV	Profit/(Loss) for the period (XI - XIV)	1,785	1,503	(129)	3,288	(631)	2,063
XVI	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss						
	B (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	1,785	1,503	(129)	3,288	(631)	2,063
XVIII	Earnings per Share :						
	(1) Basic	1.19	1.00	(0.09)	2.19	(0.42)	1.38
	(2) Diluted						

Notes :

- 1 This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- 2 The above Unaudited Financial Results for the Quarter & Half Year Ended 30.09.2019 have been reviewed by the Audit Committee in their Meeting held on 22.10.2019 and approved by the Board of Directors of its Meeting held on 22.10.2019. The Report of Auditors M/s VMD & Co. was also taken on record by the Board in its Meeting.
- 3 The Company is not having any Subsidiary Company.
- 4 The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

Place : Mumbai

Date : 22nd October, 2019



Ashok Somani
Ashok Somani
 Director

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301
 • Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001
 • Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K
 Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE STATEMENT OF ASSETS & LIABILITIES AS ON 30TH SEPTEMBER, 2019

(Rupees in Thousands)

Sr. No.	PARTICULARS	As at 30.09.2019 Unaudited	As at 31.03.2019 Audited
1	<u>ASSETS</u>		
1	Non-Current Assets		
	(A) Property, Plant & Equipment	954	30
	(B) Financial Assets		
	(i) Investment	369	369
	(ii) Long Term Loans	18,417	18,417
	Total Non-Current Assets	19,740	18,816
2	Current Assets		
	(i) Cash & Cash Equivalents	6,440	4,662
	(ii) Loans	80,750	80,732
	Total Current Assets	87,190	85,394
	TOTAL ASSETS	106,930	104,210
2	<u>EQUITY AND LIABILITIES</u>		
1	<u>Equity</u>		
	(a) Equity Share Capital	15,000	15,000
	(b) Other Equity (Reserve & Surplus)	91,584	88,296
	Total Equity	106,584	103,296
2	<u>Liabilities</u>		
1	Non-Current Liabilities	-	-
2	Current Liabilities		
	(i) Borrowings	-	-
	(ii) Other Current Liabilities	1,197	1,197
	(iii) Provisions	(851)	(283)
	Total Current Liabilities	346	914
	TOTAL EQUITY AND LIABILITIES	106,930	104,210



Ashok Somani

Ashok Somani
Director

Place : Mumbai

Date : 22nd October, 2019

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSC. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301
 Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001
 • Tel.No. (022) 22078381, 22078382 • Fax No.: (022) 22074294 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K
 Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER, 2019

(Rs. In Thousand)

PARTICULARS	STANDALONE					
	UNAUDITED QUARTER ENDED			UNAUDITED HALF YEAR ENDED		AUDITED
	30.09.2019	30.06.2019	30.09.2018	30.09.2019	30.09.2018	31.03.2019
Reconciliation of Profit After Tax as reported earlier:						
Net Profit / (Loss) for the Period (as per AS)	1,785.00	1,503.00	(129.00)	3,288.00	(631.00)	2,063
Benefit / (Charge):	-	-	-	-	-	-
Impact of Deferred Income (Government Grant) Amortized to Income	-	-	-	-	-	-
Impact of Fair Valuation of Financial Instruments	-	-	-	-	-	-
Impact of Actuarial Gain / Loss Taken OCI	-	-	-	-	-	-
Impact of Adjustment of Deferred Tax	-	-	-	-	-	-
Net Profit / (Loss) for the Period (as per AS)	1,785.00	1,503.00	(129.00)	3,288.00	(631.00)	2,063



Ashok Somani

Ashok Somani
Director

Mumbai, 22nd October, 2019